15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $5.9B | $566M | 0.0% | 0.0% | $439M | — | $72M |
| 2024 | $5.4B | $456M | 0.0% | 0.0% | $360M | — | $85M |
| 2023 | $4.8B | $352M | 0.0% | 0.0% | $268M | — | $69M |
| 2022 | $4.3B | $271M | 0.0% | 12.4% | $122M | — | $22M |
| 2021 | $4.0B | $412M | 0.0% | 13.9% | $170M | — | $49M |
| 2020 | $3.6B | $284M | 0.0% | 15.8% | — | — | $186M |
| 2019 | $4.6B | $359M | 0.0% | 13.3% | — | — | $60M |
| 2018 | $4.3B | $292M | 0.0% | 13.0% | — | — | $69M |
| 2017 | $3.9B | $271M | 0.0% | 14.8% | — | — | $54M |
| 2016 | $3.6B | $248M | 0.0% | 16.1% | — | — | $41M |
| 2015 | — | $183M | — | — | — | — | $62M |
| 2014 | — | $222M | — | — | — | — | $67M |
| 2013 | — | $324M | — | — | — | — | $65M |
| 2012 | — | $185M | — | — | — | — | $133M |
| 2011 | — | $209M | — | — | — | $1.3B | $30M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $1.6B | $195M | 0.0% | 0.0% | $151M | — | $111M |
| Dec '25 | $1.5B | $146M | 0.0% | 0.0% | $117M | — | $72M |
| Sep '25 | $1.5B | $127M | 0.0% | 0.0% | $84M | — | $49M |
| Jun '25 | $1.5B | $142M | 0.0% | 0.0% | $113M | — | $99M |
| Mar '25 | $1.5B | $152M | 0.0% | 0.0% | $126M | — | $96M |
| Dec '24 | $1.4B | $121M | 0.0% | 0.0% | $80M | — | $85M |
| Sep '24 | $1.4B | $108M | 0.0% | 0.0% | $120M | — | $148M |
| Jun '24 | $1.3B | $114M | 0.0% | 0.0% | $61M | — | $154M |
| Mar '24 | $1.3B | $113M | 0.0% | 0.0% | $99M | — | $134M |
| Dec '23 | $1.2B | $88M | 0.0% | 0.0% | -$11M | — | $69M |
| Sep '23 | $1.2B | $85M | 0.0% | 0.0% | $66M | — | $100M |
| Jun '23 | $1.2B | $91M | 0.0% | 0.0% | $85M | — | $118M |
| Mar '23 | $1.2B | $88M | 0.0% | 0.0% | $128M | — | $85M |
| Dec '22 | $1.1B | $89M | 0.0% | 13.4% | — | — | $22M |
| Sep '22 | $1.1B | $45M | 0.0% | 11.7% | — | — | $60M |
| Jun '22 | $1.1B | $49M | 0.0% | 12.1% | — | — | $136M |
| Mar '22 | $1.1B | $88M | 0.0% | 12.4% | — | — | $77M |
| Dec '21 | $1.0B | $92M | 0.0% | 12.3% | — | — | $49M |
| Sep '21 | $1.0B | $100M | 0.0% | 14.0% | — | — | $66M |
| Jun '21 | $1.0B | $113M | 0.0% | 14.7% | — | — | $73M |
How the market has priced EHC against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Encompass Health Corp's revenue has grown 10.7% per year, and net income grown 14.8% per year. These are computed facts, not advice.
As of FY2025, Encompass Health Corp reported — of total debt against $72M of cash.
In FY2025, gross margin was —, operating margin —, and net margin 9.5%.
As of Jun '26, Encompass Health Corp traded at a price-to-earnings ratio of about 17.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.